De Novo Glycan Characterization

Glycome Technologies Inc. is an innovator in glycoanalytic tools and consulting services for the biopharmaceutical industry. With its advanced methodologies and technology, GT produces the most detailed and comprehensive glycoanalytic results in the industry, generating unprecedented data quality, accuracy, and structural detail. Through tailored services and timely results delivery, GT provides superior customer value.

Importance of Glycosylation — Information through Automation

Glycans play a key role in the efficacy and safety of most protein therapeutics. Complete, detailed identification and characterization of the glycoprotein's glycan substituents allows a company to determine the glycoprotein isoforms with the highest therapeutic potential and creates an opportunity to optimize a drug's therapeutic profile. Moreover, regulatory agencies expectations for protein therapeutic approval have become increasingly stringent with regard to product characterization and safety (EMEA 2007 102, ICH 2006 103). Since many therapeutic characteristics such as pharmacokinetic stability, bioactivity and tissue specific targeting are dictated by glycans, we expect that these regulatory expectations will continue to increase over time.

By streamlining glycoanalytic processes through semi-automated and automated data acquisition and interpretation, Glycome Technologies Inc. alleviates the severe time burden and adverse consequences that result from non-standard and non-automated glycan characterization. By using our software, gtSuite, companies increase knowledge, efficiency and standardization, which results in greater certainty for companies and regulatory bodies.